Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Kymera Therapeutics (KYMR)
NASDAQ:KYMR
Kymera Therapeutics (KYMR) Stock Price & Analysis
173 Followers
KYMR Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$9.60 - $45.31
Previous Close$33.97
Volume627.45K
Average Volume (3M)668.93K
Market Cap
$2.08B
Enterprise Value$1.79B
Total Cash (Recent Filing)$374.88M
Total Debt (Recent Filing)$84.67M
Price to Earnings (P/E)-13.5
Beta2.18
Next Earnings
May 02, 2024EPS Estimate
-$0.72Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.52
Shares Outstanding61,111,678
10 Day Avg. Volume521,658
30 Day Avg. Volume668,933
Standard Deviation0.25
R-Squared0.21
Alpha0.01
Financial Highlights & Ratios
Price to Book (P/B)5.26
Price to Sales (P/S)43.35
Price to Cash Flow (P/CF)64.50
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue22.72
Enterprise Value/Gross Profit22.72
Enterprise Value/Ebitda-12.46
Forecast
1Y Price Target
$43.10Price Target Upside26.88% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering12
Kymera Therapeutics News
Bulls Say, Bears Say
Bulls Say
Clinical Trial UpdatesThe company anticipates concluding enrollment for KT-474's phase 2 trials by the end of the year with a readout expected in the first half of the following year.
Drug Development ProgressKymera's development of KT-294 aims to provide complete suppression of TYK2, potentially improving efficacy over existing treatments.
Investment PotentialAnalyst reiterates a Buy rating and increases the price target from $30 to $46 based on the momentum of Kymera’s pipeline assets and their potential.
Bears Say
Drug SafetyThe incomplete recovery of STAT3 in normal cells could be associated with toxicity issues as patients remain on the drug for an extended period.
Financial PerformanceKymera's Q4 results showed a net loss despite collaboration revenue, indicating potential financial challenges ahead.
Product PipelineThe I&I programs are early, and meaningful catalysts are more in the 2025+ timeframe, suggesting a longer wait for significant clinical data updates.
---
Ownership Overview
38.22% Insiders
28.34% Mutual Funds
15.21% Other Institutional Investors
18.24% Public Companies and
Individual Investors
KYMR FAQ
What was Kymera Therapeutics’s price range in the past 12 months?
Kymera Therapeutics lowest stock price was $9.60 and its highest was $45.31 in the past 12 months.
What is Kymera Therapeutics’s market cap?
Currently, no data Available
When is Kymera Therapeutics’s upcoming earnings report date?
Kymera Therapeutics’s upcoming earnings report date is May 02, 2024 which is in 9 days.
How were Kymera Therapeutics’s earnings last quarter?
Kymera Therapeutics released its earnings results on Feb 22, 2024. The company reported -$0.25 earnings per share for the quarter, beating the consensus estimate of -$0.404 by $0.154.
Is Kymera Therapeutics overvalued?
According to Wall Street analysts Kymera Therapeutics’s price is currently Undervalued.
Does Kymera Therapeutics pay dividends?
Kymera Therapeutics does not currently pay dividends.
What is Kymera Therapeutics’s EPS estimate?
Kymera Therapeutics’s EPS estimate is -$0.72.
How many shares outstanding does Kymera Therapeutics have?
Kymera Therapeutics has 61,111,680 shares outstanding.
What happened to Kymera Therapeutics’s price movement after its last earnings report?
Kymera Therapeutics reported an EPS of -$0.25 in its last earnings report, beating expectations of -$0.404. Following the earnings report the stock price went up 4.706%.
Which hedge fund is a major shareholder of Kymera Therapeutics?
Among the largest hedge funds holding Kymera Therapeutics’s share is Baker Bros Advisors LP. It holds Kymera Therapeutics’s shares valued at 153M.
---
Kymera Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$43.10 (26.88% Upside)
$43.10 (26.88% Upside)
Blogger Sentiment
Bullish
KYMR Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 1.2M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $304.6K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▲ 1.8%
Last 30 Days ▼ 14.5%
Last 30 Days ▼ 14.5%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-1.73%
12-Months-Change
Fundamentals
Return on Equity
-33.21%
Trailing 12-Months
Asset Growth
-4.54%
Trailing 12-Months
Company Description
Kymera Therapeutics
Kymera Therapeutics Inc is a biotechnology company pioneering a transformative new approach to treating previously untreatable diseases. The company is advancing the field of targeted protein degradation, accessing the body's innate protein recycling machinery to degrade dysregulated, disease-causing proteins. Kymera's Pegasus targeted protein degradation platform harnesses the body's natural protein recycling machinery to degrade disease-causing proteins, with a focus on un-drugged nodes in validated pathways currently inaccessible with conventional therapeutics. It is accelerating drug discovery with an unmatched ability to target and degrade the intractable of proteins, and advance new treatment options for patients.
---
KYMR Earnings Call
Q4 2024
0:00 / 0:00
---
KYMR Stock 12 Months Forecast
Average Price Target
$43.10
▲(26.88% Upside)
Technical Analysis
AbCellera Biologics
―
Crispr Therapeutics AG
―
Intellia Therapeutics
―
Kura Oncology
―
Best Analysts Covering KYMR
1 Year
1 Year Success Rate
6/10 ratings generated profit
1 Year Average Return
+24.93%
reiterated a buy rating 2 months ago
Copying Bradley Canino's trades and holding each position for 1 Year would result in 60.00% of your transactions generating a profit, with an average return of +24.93% per trade.
---